engleski

Pentadecapeptide bpc 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin

Stable gastric pentadecapeptide BPC 157 has been described in numerous studies that proved its cytoprotective effect. Recently, in rat abdominal aorta anastomosis the pentadecapeptide BPC 157 prevents obstructive thrombus formation and rapidly destroys already formed obstructive thrombus. Also, BPC 157 improves healing of various tissues, speeds up wound healing process, and decreases bleeding. Here, the results show that BPC 157 (10 μg/kg, 10 ng/kg) reduced bleeding time and reduced blood loss (after tail amputation) in rats without administration and after administration of heparin (25.000 IU/kg, 2.500 IU/kg, 1.000 IU/kg i.v.), warfarin (1.5 mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1 g/kg i.g. (once daily for 3 consecutive days) or 1.0 g/kg i.p. once). BPC 157 counteracting regimens (i.v., i.p., i.g. (immediately after any challenge)) correspondingly follow the route of bleeding-agents (heparin, aspirin, warfarin) application. All rats that received BPC 157 (treated with heparin, warfarin and aspirin, and normal (untreated) rats) had a shorter bleeding time, a smaller amount of blood loss, and a smaller decrease in platelets count. BPC 157 attenuated prolonged APTT and TT values in rats that were treated with heparin (1.000 IU/kg), but has no effect on anti-Xa activity. Indicatively, BPC 157 in rats, apart from counteracted excessive bleeding and acute thrombocytopenia (<20% of initial values in heparin-rats) has an effect on the fall in platelets count known in HIT. Also, BPC 157 markedly prolongs the survival time in rats treated with heparin 2.500 IU/kg after foot amputation. Therefore, we can conclude that the application of pentadecapeptide BPC 157 reduces bleeding, reduces blood loss, and thrombocytopenia in rats treated with heparin, aspirin and warfarin regardless of the manner of its application (intravenous, intragastrical, intraperitoneally).

Pentadecapeptide ; BPC 157 ; bleeding ; thrombocytopenia ; amputation ; rats ; heparin ; warfarin ; aspirin

nije evidentirano